BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33383383)

  • 1. Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study.
    Gebhardt C; Simon SCS; Weber R; Gries M; Mun DH; Reinhard R; Holland-Letz T; Umansky V; Utikal J
    Cell Immunol; 2021 Feb; 360():104274. PubMed ID: 33383383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model.
    Sevko A; Michels T; Vrohlings M; Umansky L; Beckhove P; Kato M; Shurin GV; Shurin MR; Umansky V
    J Immunol; 2013 Mar; 190(5):2464-71. PubMed ID: 23359505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
    Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
    Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation.
    Umansky V; Sevko A
    Cancer Immunol Immunother; 2012 Feb; 61(2):275-282. PubMed ID: 22120757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. uPAR
    Porcelli L; Guida M; De Summa S; Di Fonte R; De Risi I; Garofoli M; Caputo M; Negri A; Strippoli S; Serratì S; Azzariti A
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade.
    Mukherjee N; Katsnelson E; Brunetti TM; Michel K; Couts KL; Lambert KA; Robinson WA; McCarter MD; Norris DA; Tobin RP; Shellman YG
    Cell Death Dis; 2024 Mar; 15(3):198. PubMed ID: 38459020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma.
    Umansky V; Blattner C; Gebhardt C; Utikal J
    Cancer Immunol Immunother; 2017 Aug; 66(8):1015-1023. PubMed ID: 28382399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.
    Krebs FK; Trzeciak ER; Zimmer S; Özistanbullu D; Mitzel-Rink H; Meissner M; Grabbe S; Loquai C; Tuettenberg A
    Cancer Med; 2021 Mar; 10(5):1562-1575. PubMed ID: 33449393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.
    Fujimura T; Aiba S
    Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32707850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonality of CD4
    Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
    Front Immunol; 2019; 10():1336. PubMed ID: 31275310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab.
    Tobin RP; Jordan KR; Robinson WA; Davis D; Borges VF; Gonzalez R; Lewis KD; McCarter MD
    Int Immunopharmacol; 2018 Oct; 63():282-291. PubMed ID: 30121453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.
    de Coaña YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nyström M; Edbäck U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
    Oncotarget; 2017 Mar; 8(13):21539-21553. PubMed ID: 28423487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
    Saito R; Sawada Y; Nakamura M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.
    Qiu H; Zmina PM; Huang AY; Askew D; Bedogni B
    Cancer Lett; 2018 Oct; 434():144-151. PubMed ID: 30036609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenformin Inhibits Myeloid-Derived Suppressor Cells and Enhances the Anti-Tumor Activity of PD-1 Blockade in Melanoma.
    Kim SH; Li M; Trousil S; Zhang Y; Pasca di Magliano M; Swanson KD; Zheng B
    J Invest Dermatol; 2017 Aug; 137(8):1740-1748. PubMed ID: 28433543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
    Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA
    Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.
    Yan Y; Cao S; Liu X; Harrington SM; Bindeman WE; Adjei AA; Jang JS; Jen J; Li Y; Chanana P; Mansfield AS; Park SS; Markovic SN; Dronca RS; Dong H
    JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.